NYSE Analytics: July 22, 2014
NYSE Analytics: July 22, 2014
Spyder ETF grows before NYSE opening bell.
SPY (intraday chart) uptrend on premarket. Support 197.50, resistance 198.00.
Gapping up/down: SANM +12%, CMG +11%, ARMH +5% after earnings, AXL and QSII +1% after ugrades; EDU -8% and KO -1% after earnings, NILE -2% after dg.
In reaction to strong earnings/guidance:
SANM +11.8%, CIT +11.8%, CMG +10.6%, WWD +7.6%,STLD +7.5%, TGTX +5.4%, (also announces preliminary clinical results from its ongoing Phase I study of TG-1101 (ublituximab): 100% of CLL/SLL patients had significant nodal reduction with either a normalization of or =80% reduction in Blood Lymphocyte Count), HLX +4.8%, ARMH +4.8%, CROX +4.6%, PII +4.4%,CYS +3.7%, MOSY +3%, LMT +2.5%, CMCSA +2.2%,
DPZ +2.2%, CNC +2.1%, PKG +2%, UTX+1.3%, CNI +1.1%, RF +0.5%, STT +0.4%, NFLX +0.3%.
M&A news: GTIV +0.9% (announces receipt of acquisition proposal from Kindred Healthcare (KND)).
Select alt energy related names showing strength after German Govt issued research awards: FCEL+5%, KNDI +4.2%, PLUG +3.5%.
Select semi peers trading higher after TXN and ARMH earnings: STM +2%, AMD +1.1%, MU+0.8%.
Select oil/gas related names showing strength following strength in Crude oil market: TOT +1.3%,RDS.A +0.9%, BP +0.5%.
Other news: RSH +7.2% (still checking), FBRC +6.6% ( announces self tender offer to purchase up to one mln shares, or about 9.9%, of its outstanding common stock, at a price of not less than $28 and not more than $29 per share), SNTA +5.7% (announces advancement of Ganetespib into Phase 3 Extension of AML LI-1 study for patients with AML and High-Risk MDS; follows positive interim analysis of Phase 2 results), GST+3.6% (reported 43% increase in mid-year proved reserves), GPRO +2.7% (still checking), GALE +2.5% (enters into definitive agreement to license U.S. rights for Zuplenz (ondansetron) oral soluble film), RDC +2.2% (Blue Harbour Group discloses 6.5% stake in SC 13D filing; expects to continue to engage in discussions with management and the board), MM +1.3% (following Yahoo (YHOO) acquisition of mobile-analytics co Flurry; MM is a mobile advertising platform company), EVGN +1.3% (co and Marrone Bio Innovations (MBII) sign multi-year collaborative agreement; joint discovery efforts to lead to novel insect control solutions), ERIC +1.1% (chosen as sole supplier of Claro’s LTE network in Costa Rica), FITB +1% (Fifth Third disclosed share repurchase agreement with Morgan Stanley), AAPL +0.9% (requested that suppliers produce 80 mln large screen iPhones, according to reports (AAPL reports tonight after the close)).
Analyst comments: AXL +1% (upgraded to Neutral from Underweight at JP Morgan), QSII +0.9% (initiated with a Buy at Topeka Capital Markets ), HBAN +0.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
In reaction to disappointing earnings/guidance:
EDU -8.1%, UCTT -4.5%, ATR -2.9%, RMBS -2.6%,STFC -2.3%, CS -2.2%, POL -2%, KMB -1.8%, TRV -1.7%,
HOG -1.6%, RCII -1%, VZ -1%, KO-0.9%.
Select metals/mining stocks trading lower: GDX -0.9%, GFI -0.8%, ABX -0.5%.
Other news: TEP -4.8% (announced self tender offer to purchase up to 1 mln shares, or about 9.9%, of its outstanding common stock, at a price of not less than $28 and not more than $29 per share), ITI -2.1% (announces receipt of Notice of Noncompliance with NYSE MKT Listing Standards ), TWX -0.5% (discloses bylaw amendment; removed provisions regarding stockholders’ ability to cause Board to call a special meeting of stockholders), ACT -0.5% (co and Medicines360 announced FDA acceptance for filing of NDA for Levosert IUD).
Analyst comments: NILE -2% (downgraded to Mkt Perform from Outperform at William Blair), AMZN-1.6% (downgraded to Neutral from Buy at Citigroup), ARCO -1.5% (downgraded to Underweight from Neutral at HSBC Securities), STI -0.7% (downgraded to Equal Weight from Overweight at Evercore).
Trading Ideas NYSE & NASDAQ:
- TEP – short below premarket low
- EDU – short below 23.00
- HOG – short below 65.00
- HLF -long above 54.00
- CROX – short below 15.50